RxDoctor Payments Data

Karen Allen, MD

Dermatology · San Luis Obispo, CANPI 1942200183

Payments from drug & device makers

$13,272in general payments, 2019–2025

Across 572 payments — averaging $23.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Daiichi Sankyo Inc.$959
  • Amgen$812
  • AstraZeneca$762
  • E.r. Squibb & Sons, L.L.C.$680
  • Seagen Inc.$616
  • plus $8K from 54 others

What the payments were for

  • Food & beverage$13,219100%
  • Education$520%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson44$1,253
Daiichi Sankyo Inc.56$959
Amgen35$812
AstraZeneca(2 entities)38$762
E.r. Squibb & Sons, L.L.C.25$680
Seagen Inc.36$616
Blueprint Medicines Corporation14$540
Eisai Inc.30$522
Merck26$506
Lilly USA, LLC8$396
Takeda Pharmaceuticals U.S.A., Inc.18$344
Sobi, Inc11$335
Exelixis Inc.10$324
Pfizer6$313
Regeneron Healthcare Solutions, Inc.9$295
Novartis17$294
Bayer17$280
EMD Serono, Inc.10$260
Incyte Corporation15$258
Sanofi7$213
GSK4$206
Dendreon Pharmaceuticals LLC7$172
Puma Biotechnology, Inc.9$172
Alnylam Pharmaceuticals Inc.4$169
Janssen Scientific Affairs, LLC1$144
AMAG Pharmaceuticals, Inc.7$140
AbbVie2$138
Genentech USA, Inc.7$136
Rigel Pharmaceuticals, Inc.7$128
Organogenesis Inc.1$123
Jazz Pharmaceuticals Inc.6$119
Morphosys, US Inc.7$118
Karyopharm Therapeutics Inc.5$106
Bristol Myers Squibb4$102
Array Biopharma Inc5$100
Clovis Oncology, Inc.6$100
Boehringer Ingelheim4$82
Ipsen Biopharmaceuticals, Inc4$75
Secura Bio, Inc.1$58
Tesaro, Inc.4$54
ADC Therapeutics America, Inc.2$52
Syndax Pharmaceuticals, Inc.2$52
Apellis Pharmaceuticals, Inc.2$50
Taiho Oncology, Inc.2$48
Pharmacyclics LLC, An Abbvie Company2$47
Mirati Therapeutics, Inc.3$47
Recordati_rare_diseases_inc.2$41
Tolmar Pharmaceuticals, Inc.2$40
Coherus Oncology, Inc.1$38
Epizyme, Inc.2$32
Acrotech Biopharma Inc.2$30
Heron Therapeutics, Inc.3$27
Myriad Genetic Laboratories, Inc.1$25
Stemline Therapeutics Inc.1$25
Pharmaessentia USA Corporation1$25
Kyowa Kirin, Inc.1$24
Gilead1$22
Fresenius Kabi USA, LLC1$21
Beone Medicines USA, Inc.1$19
Servier Pharmaceuticals LLC1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,272 in reported general payments places this provider in the 80th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$189,329
Medicare patients
623
Services billed
3,173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Fluorouracil17$1,111
Clobetasol Propionate20$718
Imiquimod11$595
Ketoconazole18$440
ValacyclovirValacyclovir Hcl22$395
Mupirocin17$119

Paid to pharmacies, not to this prescriber.

Other dermatology in San Luis Obispo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →